Search

Your search keyword '"Coello, V."' showing total 6 results
Start Over Author "Coello, V." Publisher bmj
6 results on '"Coello, V."'

1. AB1101 PREVALENCE OF LONG COVID IN RHEUMATIC DISEASE PATIENTS: ANALYSIS OF SAR COVID REGISTRY

Author

Gonzalez Gomez, C. A., primary, Cosatti, M., additional, Castro Coello, V. V., additional, Haye, M., additional, Tissera, Y., additional, Reyes, A. A., additional, Albiero, J. A., additional, Ornella, S., additional, Alba, P., additional, Gobbi, C., additional, Gamba, M. J., additional, Exeni, I. E., additional, Cusa, A., additional, Gallino Yanzi, J., additional, Bellomio, V. I., additional, Gomez, G., additional, Zelaya, D., additional, Takashima, L., additional, Carlevaris, L., additional, Correa, M. D. L. A., additional, Rojas Tessel, R., additional, García, M., additional, German, N., additional, Mercé, A. L., additional, Bertoli, A., additional, Aguero, S. E., additional, Calvo, M. E., additional, Martire, V., additional, Mauri, M., additional, Martin, M. L., additional, Picco, E., additional, Castrillon Bustamante, D., additional, Ibañez Zurlo, L., additional, Tamborenea, M. N., additional, Subils, G. C., additional, Vasquez, D. L., additional, Soares de Souza, S., additional, Herscovich, N., additional, Raiti, L., additional, Cosentino, V., additional, Rodriguez, F., additional, Ledesma, C., additional, Diaz, M. P., additional, Mamani Ortega, M. L., additional, Castaño, M. S., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, Isnardi, C. A., additional, Pons-Estel, G., additional, and Pisoni, C., additional

Published
2022
Full Text
View/download PDF

2. POS1238 GLUCOCORTICOIDS, RITUXIMAB AND THE PRESENCE OF INTERSTITIAL LUNG DISEASE ARE ASSOCIATED WITH POOR OUTCOMES OF THE SARS-COV-2 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL REGISTRY SAR-COVID.

Author

Gómez Vara, A. B., primary, Barbich, T., additional, Isnardi, C. A., additional, Schneeberger, E. E., additional, Citera, G., additional, Castro Coello, V. V., additional, Baez, R., additional, Haye, M., additional, Reyes, A. A., additional, Albiero, J. A., additional, Tanten, R., additional, Velozo, E., additional, Alba, P., additional, Gamba, M. J., additional, Alonso, C. G., additional, Maldonado Ficco, H., additional, Gallino Yanzi, J., additional, Savio, V., additional, Asnal, C., additional, Matellan, C., additional, Takashima, L., additional, Carlevaris, L., additional, Gálvez Elkin, M. S., additional, Scafati, J., additional, García, M., additional, German, N., additional, Werner, M. L., additional, Aeschlimann, C., additional, Aguero, S. E., additional, Calvo, M. E., additional, Gonzalez Lucero, L., additional, Rodriguez Gil, G. F., additional, Mauri, M., additional, Petruzzelli, S., additional, Castrillon Bustamante, D., additional, Ibañez Zurlo, L., additional, Alonso, D., additional, Tomas, J. L., additional, Vasquez, D. L., additional, Soares de Souza, S., additional, Herscovich, N., additional, Raiti, L., additional, Mareco, J. M., additional, Guaglianone, D., additional, Ledesma, C., additional, Diaz, M. P., additional, Bedoya, M. E., additional, Kisluk, B., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, and Pons-Estel, G., additional

Published
2022
Full Text
View/download PDF

3. AB0342 OBSTETRIC AND THROMBOTIC ANTIPHOSPHOLIPID SYNDROME: ARE THEY DIFFERENT ENTITIES?

Author

Serrano Morales, R., primary, Nieto, R., additional, Porta, S., additional, Roberts, K., additional, Lema, L., additional, Maldini, C., additional, Tissera, Y., additional, Albiero, J. A., additional, Savio, V., additional, Goizueta, C., additional, Lobo, V., additional, Broll, A., additional, Cucchiaro, N., additional, ¨perez, S., additional, Izaguirre, P., additional, Estevez, A., additional, Abalo, A. I., additional, Etcheverry, M., additional, Bellomio, V. I., additional, Leguizamón, M. L., additional, Antoniol, N., additional, Perandones, C., additional, Pisoni, C., additional, De la Torre, M. L., additional, García, M., additional, Velloso, M. S., additional, Sacnun, M., additional, Gobbi, C., additional, Guaglione, D., additional, Vivero, F., additional, Saurit, V., additional, Benzaquen, N., additional, Nemman, V., additional, Remondino, G., additional, Machado Escobar, M., additional, Scolnik, M., additional, Danielsen, C., additional, Gomez, G., additional, Babini, A. M., additional, Brigante, A., additional, Luissi, A., additional, Castro Coello, V. V., additional, Sorrentino, L., additional, Berman, H., additional, Alba, P., additional, and Pons-Estel, G., additional

Published
2021
Full Text
View/download PDF

4. POS1208 EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE ARGENTINEAN SAR-COVID REGISTRY

Author

Isnardi, C. A., primary, Quintana, R., additional, Roberts, K., additional, Castro Coello, V. V., additional, Reyes, A. A., additional, Tissera, Y., additional, Cosatti, M., additional, Rojas Tessel, R., additional, Scafati, J., additional, Barbich, T., additional, Gálvez Elkin, M. S., additional, Rodriguez Gil, G. F., additional, Moyano, S., additional, Werner, M. L., additional, Rebak, J., additional, Morbiducci, J., additional, Martire, V., additional, Castaño, M. S., additional, Dieguez, C., additional, Subils, G. C., additional, and Pons-Estel, G., additional

Published
2021
Full Text
View/download PDF

5. POS1186 EFFECT OF SOCIO-ECONOMIC STATUS AND EDUCATIONAL LEVEL ON COVID-19 OUTCOMES IN PATIENTS WITH RHEUMATIC DISEASES FROM ARGENTINA: DATA FROM THE SAR-COVID REGISTRY

Author

Sorrentino, L., primary, Rebak, J., additional, Maldonado, F., additional, Castro Coello, V. V., additional, Brigante, A., additional, Hamaui, A., additional, Dubinsky, D., additional, Baez, R., additional, Pisoni, C., additional, Gobbi, C., additional, Carlevaris, L., additional, Tanten, R., additional, Cogo, A. K., additional, Delavega, M., additional, Perez Alamino, R., additional, Lazaro, M. A., additional, Pera, M., additional, Pineda Vidal, S. I., additional, Calvo, M. E., additional, Guaglianone, D., additional, Alonso, C. G., additional, Guinsburg, M., additional, Retamozo, C., additional, Aeschlimann, C., additional, Quintana, R., additional, Roberts, K., additional, Isnardi, C. A., additional, and Pons Estel, G., additional

Published
2021
Full Text
View/download PDF

6. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance.

Author

Ugarte-Gil MF, Alarcón GS, Izadi Z, Duarte-García A, Reátegui-Sokolova C, Clarke AE, Wise L, Pons-Estel GJ, Santos MJ, Bernatsky S, Ribeiro SLE, Al Emadi S, Sparks JA, Hsu TY, Patel NJ, Gilbert EL, Valenzuela-Almada MO, Jönsen A, Landolfi G, Fredi M, Goulenok T, Devaux M, Mariette X, Queyrel V, Romão VC, Sequeira G, Hasseli R, Hoyer B, Voll RE, Specker C, Baez R, Castro-Coello V, Maldonado Ficco H, Reis Neto ET, Ferreira GAA, Monticielo OAA, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Costello W, Wallace ZS, Jacobsohn L, Taylor T, Ja C, Strangfeld A, Mateus EF, Hyrich KL, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schäfer M, Machado PM, Robinson PC, Gianfrancesco M, and Yazdany J

Subjects
Humans, Male, Prednisone therapeutic use, Severity of Illness Index, COVID-19, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic drug therapy, Rheumatology
Abstract

Aim: To determine characteristics associated with more severe outcomes in a global registry of people with systemic lupus erythematosus (SLE) and COVID-19., Methods: People with SLE and COVID-19 reported in the COVID-19 Global Rheumatology Alliance registry from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised with no oxygenation, (3) hospitalised with any ventilation or oxygenation and (4) death. A multivariable ordinal logistic regression model was constructed to assess the relationship between COVID-19 severity and demographic characteristics, comorbidities, medications and disease activity., Results: A total of 1606 people with SLE were included. In the multivariable model, older age (OR 1.03, 95% CI 1.02 to 1.04), male sex (1.50, 1.01 to 2.23), prednisone dose (1-5 mg/day 1.86, 1.20 to 2.66, 6-9 mg/day 2.47, 1.24 to 4.86 and ≥10 mg/day 1.95, 1.27 to 2.99), no current treatment (1.80, 1.17 to 2.75), comorbidities (eg, kidney disease 3.51, 2.42 to 5.09, cardiovascular disease/hypertension 1.69, 1.25 to 2.29) and moderate or high SLE disease activity (vs remission; 1.61, 1.02 to 2.54 and 3.94, 2.11 to 7.34, respectively) were associated with more severe outcomes. In age-adjusted and sex-adjusted models, mycophenolate, rituximab and cyclophosphamide were associated with worse outcomes compared with hydroxychloroquine; outcomes were more favourable with methotrexate and belimumab., Conclusions: More severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes., Competing Interests: Competing interests: MFU-G has received research grants from Pfizer and Janssen, not related to this manuscript. AD-G is supported by the Rheumatology Research Foundation (Scientist Development Award) and the Centers for Disease Control and Prevention. CR-S has received research grants from Janssen, not related to this manuscript. AEC has received consulting fees from AstraZeneca, BMS and GSK, all unrelated to this manuscript. LW has received consulting fees and speaker’s honoraria from Aurinia Pharma unrelated to this manuscript. GJP-E reports no competing interests related to this work. Outside of this work, he reports personal consulting and/or speaking fees from Pfizer, GSK, Janssen and Sanofi (all

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results